Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...

2025 Healthcare & Pharmaceuticalscategory Roche fails in bid to increase dose of MS drug Ocrevus April 2, 2025 Healthcare & Pharmaceuticalscategory US Supreme Court largely backs FDA's denial of ...

Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic ...

TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) have significantly outperformed the industry in a year. The stock has ...

Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain ...

Earnings preview of key companies reporting next week and what to look out for. The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma ...

VTIP Vanguard Short-Term Inflation-Protected Securities Index Fund ETF Shares ...